RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

Rhea-AI Summary

RenovoRx, Inc. (Nasdaq: RNXT) appoints Dr. Michel Ducreux, a renowned oncologist, to its Scientific Advisory Board. Dr. Ducreux brings extensive experience in gastrointestinal oncology and research, and is expected to contribute to the advancement of the Company's novel clinical programs.

LOS ALTOS, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI.

Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master’s degree in biological sciences and PhD in health sciences. He has held previous positions as assistant physician and professor of oncology at the Gastrointestinal Oncology Unit of Gustave Roussy and Paul Brousse Hospital in Villejuif, France. He was a Medical Affairs Director at Gustave Roussy from January 2011 to December 2019. He is the former Chair of the European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Group and the former Chair of the Gastrointestinal Group of the French Federation of Anticancer Centers (FNCLCC). He is a co-editor for gastrointestinal oncology of the European Journal of Cancer.

“I am excited to be working with my distinguished colleagues on RenovoRx’s Scientific Advisory Board,” stated Dr. Ducreux. “I look forward to contributing to the advancement of the Company’s novel clinical programs that have the potential to revolutionize the treatment of challenging cancers.”

Dr. Ducreux added, “Having previously worked on intra-arterial and intra-tumoral delivery, what excites me most about RenovoRx’s published data is its platform delivery mechanism. The trans-arterial micro-perfusion platform appears to unlock best-in-class improvements to increase local therapeutic tissue concentration with deep tissue penetration to overcome dense tumor microenvironments while avoiding dose-limiting systemic toxicities beyond conventional intra-tumoral and traditional intra-arterial delivery. This platform has the potential to extend across a variety of high unmet needs beyond targeted delivery of gemcitabine and pancreatic tumors.”

Professor Ducreux has published more than 500 scientific articles, with papers for which he was the lead author, focusing on the management of metastatic colorectal cancer, locally advanced and metastatic pancreatic carcinoma, biliary tract carcinoma, hepatocellular carcinoma, and treatment of neuroendocrine tumors. He has been a speaker at over 200 invited lectures in various national and international congresses.

“Dr. Ducreux is an internationally recognized clinical expert and researcher who has made pioneering contributions to the field of gastrointestinal cancers,” said Shaun Bagai, CEO of RenovoRx. “We are honored to welcome Dr. Ducreux to our SAB. His extensive knowledge on pancreatic and other gastrointestinal cancers and the development of novel therapeutic approaches will be invaluable to our R&D initiative. This appointment enhances the already deep expertise resident in our growing SAB. We look forward to Dr. Ducreux’s guidance as we advance our therapy platform, TAMP™, for targeted treatment of difficult-to-access tumors, like locally advanced pancreatic cancer (LAPC), and expand to other clinical indications in our pipeline.”

About RenovoRx, Inc.

RenovoRx is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. The Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP^TM) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic (intravenous (IV) therapy). RenovoRx’s unique approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate, RenovoGem^TM, a novel oncology drug-device combination product, is being investigated under a US IND that is regulated by FDA 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research (the drug division of FDA.) RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and Twitter.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding our clinical trials and studies, including anticipated timing, statements regarding the potential of RenovoCath^®, RenovoGem^TM or TAMP^TM or regarding our ongoing TIGeR-PaC Phase III clinical trial study in LAPC, statements regarding the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and our preliminary financial results, cash position and related ability to continue as a going concern. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, clinical trials, therapy platform, business plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our research programs; the possibility that interim results may not be predictive of the outcome of our clinical trial, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, or the regulatory authority may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; our ability to use and expand our therapy platform to build a pipeline of product candidates; our ability to advance product candidates into, and successfully complete, clinical trials; the timing or likelihood of regulatory filings and approvals; our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; the commercialization potential of our product candidates, if approved; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; future strategic arrangements and/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified personnel; the implementation of our strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the pricing, coverage and reimbursement of our product candidates, if approved; developments relating to our competitors and our industry, including competing product candidates and therapies; negative impacts of the ongoing COVID-19 pandemic on our operations; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116495144/en/

Investor Contact:

KCSA Strategic Communications

Valter Pinto or Jack Perkins

T:212-896-1254

renovorx@kcsa.com

Media Contact:

Kimberly Ha

KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com

Source: RenovoRx, Inc.

FAQ

Who is Dr. Michel Ducreux?

Dr. Michel Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. He has extensive experience in medicine, gastroenterology, and gastrointestinal tract oncology.

What are the qualifications of Dr. Michel Ducreux?

Dr. Michel Ducreux holds a master's degree in biological sciences and a PhD in health sciences. He has held previous positions as assistant physician and professor of oncology at the Gastrointestinal Oncology Unit of Gustave Roussy and Paul Brousse Hospital in Villejuif, France.

What is the role of Dr. Michel Ducreux in RenovoRx?

Dr. Michel Ducreux joins RenovoRx's Scientific Advisory Board and aims to contribute to the advancement of the Company’s novel clinical programs that have the potential to revolutionize the treatment of challenging cancers.